GenomeXpress - Rapid Genome Sequencing with Verbal Results in 7 Days
New York
Approved
Clinical Utility
- Determination of a clinical diagnosis
- Identification of gene implicated in genetic disease
- Recurrence risk assessment
Important Information
The GenomeXpress test is an expedited nuclear genome sequencing test with a turnaround time (TAT) of approximately 2 weeks performed concurrently with mitochondrial genome sequencing and deletion testing. A verbal result for rapid nuclear genome findings is given within 7 calendar days after the start of testing and will include pathogenic and/or likely pathogenic variants in known disease-causing genes definitively explaining the patient’s phenotype. A written report including all clinically relevant variants will be reported within approximately 2 weeks after the start of testing. Concurrent mitochondrial genome test results will be provided in a separate written report within approximately 3-4 weeks after the start of testing; mitochondrial variants are not included in the verbal result.
Because of the rapid TAT, blood on the proband and both biological parents must be submitted at the same time, along with clinical information, in order to begin testing. This test requires approval by GeneDx; please email Xpress@GeneDx.com to discuss prior to sending in samples.
Insurance billing not accepted
Test Code
TH78
CPT Codes*
81425x1, 81426x2
ABN Required
No
Turnaround Time**
Verbal result in 7 days and final written report ~2 weeks for nuclear genome sequencing test; 3-4 weeks for mitochondrial genome test written report
Preferred Specimen
Alternative Specimen
*The CPT codes provided are based on AMA guidelines and are for informational purposes only. CPT coding is the sole responsibility of the billing party. Please direct any questions regarding coding to the payer being billed.
**Reporting times are typical and begin once the sample(s) are received at the GeneDx laboratory, but could be extended in situations outside GeneDx’s reasonable control.
Test Documents
Billing
Targeted Variant Testing